Nvidia Corp. will invest $1 billion over five years to establish a new artificial intelligence laboratory in collaboration with Eli Lilly & Co. The facility, located in Silicon Valley, aims to accelerate the application of AI in the pharmaceutical industry by leveraging Lilly's lab expertise.

Three MIT PhD students reverse-engineered Google's AlphaFold 3, creating Boltz-1 as an open-source alternative for drug discovery. Their platform enables pharmaceutical companies to conduct rapid and cost-effective drug-binding predictions while maintaining free access to the underlying models. Boltz aims to challenge commercial restrictions and offer a more accessible solution within the competitive landscape of AI in drug discovery.